Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - ethinylestradiol 0.01mg - tablet - 0.01 mg - active: ethinylestradiol 0.01mg excipient: acacia alginic acid ethanol lactose monohydrate magnesium stearate potato starch water - postmenopausal symptoms due to oestrogen deficiency including prevention of postmenopausal osteoporosis. in women with an intact uterus the addition of a progestogen is essential

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - sodium tetradecyl sulfate 0.2%{relative} - solution for injection - 0.2 % - active: sodium tetradecyl sulfate 0.2%{relative} excipient: benzyl alcohol dibasic sodium phosphate dodecahydrate monobasic potassium phosphate sodium hydroxide water for injection - the treatment of minor venules and spider veins (venous flares) by injection sclerotherapy.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - sodium tetradecyl sulfate 0.5%{relative} - solution for injection - 0.5 % - active: sodium tetradecyl sulfate 0.5%{relative} excipient: benzyl alcohol dibasic sodium phosphate monobasic potassium phosphate sodium hydroxide water for injection - the treatment of varicose veins and venous flares of the leg by injection sclerotherapy

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - sodium tetradecyl sulfate 1%{relative} - solution for injection - 1 % - active: sodium tetradecyl sulfate 1%{relative} excipient: benzyl alcohol dibasic sodium phosphate monobasic potassium phosphate sodium hydroxide water for injection - the treatment of varicose veins of the leg by injection sclerotherapy.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - sodium tetradecyl sulfate 3%{relative} - solution for injection - 3 % - active: sodium tetradecyl sulfate 3%{relative} excipient: benzyl alcohol dibasic sodium phosphate monobasic potassium phosphate sodium hydroxide water for injection - the treatment of varicose veins of the leg by injection sclerotherapy.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg;   - capsule - 500 mg - active: cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg   excipient: gelatin   magnesium stearate microcrystalline cellulose titanium dioxide   water  

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage);   - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage)   excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage);   - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage)   excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - betamethasone acetate 3 mg/ml; betamethasone sodium phosphate 3.9 mg/ml;   - solution for injection - active: betamethasone acetate 3 mg/ml betamethasone sodium phosphate 3.9 mg/ml   excipient: benzalkonium chloride dibasic sodium phosphate disodium edetate dihydrate monobasic sodium phosphate monohydrate water for injection

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a); influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a); influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) - suspension for injection - 9 mcg - active: influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a) influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a) influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection - intanza 9mcg is indicated for prophylaxis of influenza in adults from 18 to 59 years of age. the use of intanza 9mcg in new zealand should be based on the ministry of health recommendations for influenza vaccination as published in the current new zealand immunisation handbook.